FDA reissues emergency use authorization for COVID-19 treatment
Combination of two human monoclonal antibodies for post-exposure prophylaxis (prevention) of COVID-19 in certain patients
Drugs
The Center for Drug Evaluation and Research (CDER) ensures that safe and effective drugs are available to improve the health of the people in the United States
Topic Paragraphs
COVID-19 Updates
FDA amends emergency use authorization for COVID-19 treatment
Drug combination no longer required for the treatment of COVID-19 hospitalized patients
Know your treatment options for COVID-19
The FDA approved one drug and many more are being tested in clinical trials
Recent News
FDA-approved product for diabetes is first interchangeable biosimilar
July 28 - May be substituted at the pharmacy, potentially reducing costs for certain patients with diabetes
FDA asks to remove strongest warning against statins in pregnancy
July 20 - Despite change, most pregnant patients should stop taking statins
Summer is here - are you using your sunscreen correctly?
Test your knowledge about sunscreens with our sunscreen quiz
Trending Topics
Q&A for Consumers | Hand Sanitizers and COVID-19
Learn how the FDA and its partners are addressing the COVID-19 outbreak
High Blood Pressure–Understanding the Silent Killer
It can lead to many serious problems that’s why it’s important to know your risk factors
BeSafeRx: Your Source for Online Pharmacy Information
Explore resources and tools so you can safely buy prescription medicines online
CENTER FOR DRUG EVALUATION AND RESEARCH
Office of Communications
10001 New Hampshire Ave
Hillandale Building, 4th Fl
Silver Spring, MD 20993
10001 New Hampshire Ave
Hillandale Building, 4th Fl
Silver Spring, MD 20993
Toll Free
(855) 543-3784
(301) 796-3400
Hours Available
CDER Division of Drug Information
Paragraph Header (Column 2)
FOR UPDATES ON TWITTER FOLLOW
Paragraph Header (Column 2)
FOR UPDATES ON TWITTER FOLLOW
@FDA_Drug_Info
Your source for the latest drug information.
Know the moment it happens.